Immune to Cancer: The CRI Blog
-
AACR18 Recap: Immunotherapy in the Spotlight
Immunotherapy took center stage and dominated the headlines at AACR18.
-
AACR18 Update: Lloyd J. Old Award, Overcoming Immunotherapy Resistance, and the Importance of Dendritic Cells
Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and…
-
AACR18 Day 3 Update: Lung Cancer in the Spotlight, Immune Memory, and New Immunotherapy Biomarkers
Day 3 of AACR18 highlighted potentially “practice-changing” immunotherapy breakthroughs in lung cancer, and insights into the factors…
-
AACR18: Driving Innovative Cancer Science to Patient Care
This year’s annual AACR meeting boasts an impressive lineup of presentations highlighting both clinical and preclinical immunotherapy…
-
Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs
Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…
-
Immunotherapy Shines at ASH and ESMO IO Conferences
Two conferences, one in America and one in Europe, highlight immunotherapy's continued progress and the important contributions…
-
CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients
FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.
-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…
-
ASCO 2016 Update: Tapping into the Potential of Anti-Tumor T Cells
Adoptive T cell therapies provide success against some cancers, hope for several others.